Incyte Corp. has announced that it will be presenting 10 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016 that will feature data from its emerging development portfolio.
Incyte's abstracts will include company data from the programs developing monoclonal antibody antagonists designed to target GITR and OX40 and its small molecule inhibitors programs designed to target LSD1, BRD (BET), PI3Ko and JAK1.
Reid Huber, Chief Scientific Officer at Incyte, has stated that the company is looking forward to presenting its latest scientific data that will show off the potential of Incyte’s emerging development portfolio. He also said that the abstracts that will be presented at the AACR annual meeting demonstrate the discovery team’s groundbreaking methods for cancer research and reiterates Incyte’s dedication to the further development of novel therapeutics that could possibly help cancer patients live longer lives.
Incyte has also been invited to present “IDO1 Inhibition as a Modifier of the Immune Composition of the Tumor Microenvironment and a Component of Combination Immunotherapy for Cancer,” as part of the AACR Major Symposia called, “Cancer Immunotherapy: Small Molecule Approaches.”
The AACR Annual Meeting will be held in New Orleans from April 16-20.